Advicenne S.A. (EPA:ALDVI)

France flag France · Delayed Price · Currency is EUR
1.970
-0.010 (-0.51%)
Mar 4, 2026, 3:26 PM CET
10.67%
Market Cap 28.05M
Revenue (ttm) 5.90M
Net Income (ttm) -6.21M
Shares Out 14.17M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,077
Average Volume 56,345
Open 1.920
Previous Close 1.980
Day's Range 1.908 - 1.998
52-Week Range 1.104 - 2.350
Beta 0.76
RSI 49.33
Earnings Date Mar 26, 2026

About Advicenne

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. wa... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 13
Stock Exchange Euronext Paris
Ticker Symbol ALDVI
Full Company Profile

Financial Performance

In 2024, Advicenne's revenue was 5.27 million, a decrease of -0.51% compared to the previous year's 5.30 million. Losses were -6.46 million, -14.13% less than in 2023.

Financial Statements

News

There is no news available yet.